Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II exploratory multicohort study of AK112 with chemotherapy and/or olaparib in platinum-sensitive recurrent ovarian cancer
CTR20244161Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Feb 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in ovarian cancer, sponsored by Akeso, Inc.. Started Feb 2025; status: active.
02
Drugs
ivonescimab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on CTR20244161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244161.